ArticleFrontiers in immunology2026

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine.

Antonietta Liotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.